Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the secondâline antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, DallâEra M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the secondâline antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonths
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply